4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day

Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.

Zacks Investment Research • Sep 21, 2026

Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript

Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript

Seeking Alpha • Sep 16, 2026

Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha • Sep 10, 2026

Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026

NEWTON, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that the Company will host a virtual Investor Day on Wednesday, September 16, 2026 at 10:00 a.m. ET.

GlobeNewsWire • Sep 10, 2026

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

NEWTON, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in the following upcoming investor conferences.

GlobeNewsWire • Sep 2, 2026

Acumen Pharmaceuticals Q2 Earnings Call Highlights

Acumen Pharmaceuticals NASDAQ: ABOS said it remains on track to report top-line results late in 2026 from its Phase II ALTITUDE-AD study of sabirnetug, an investigational antibody designed to selectively target synaptotoxic amyloid-beta oligomers in early Alzheimer's disease.

MarketBeat • Aug 12, 2026

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 12, 2026

Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights

NEWTON, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the second quarter of 2026 and provided a business update.

GlobeNewsWire • Aug 12, 2026

Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026

NEWTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report second quarter financial results on Wednesday, Aug. 12, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

GlobeNewsWire • Aug 5, 2026

Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.

Zacks Investment Research • Jul 31, 2026